High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone).
Adding zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone) (ZR2-CHOP) for high-risk patients with diffuse large B-cell lymphoma (DLBCL) may result in a high complete response rate (CRR).
Researchers from China presented the findings at the European Hematology Association 2021 Virtual Congress. They conducted a single-arm retrospective observation study of 10 patients with DLBCL aged 18 to 75 years, who were enrolled between July 2020 and February 2021. Most of the patients (n = 9) were treatment naïve and 1 patient had relapsed/refractory DLBCL. This one patient experienced disease progression after 4 cycles of bendamustine plus rituximab.
Seven patients were classified as the high-intermediate and high-risk group, according to the National Comprehensive Cancer Network International Prognostic Index.
The patients received oral zanubrutinib 160 mg twice daily continuously from day 0 and lenalidomide 25 mg daily from days 1 to 7. They were given intravenously administered rituximab (375 mg/m2 day 0), cyclophosphamide (750 mg/m2 day 1), doxorubicin (50 mg/m2 day 1), vincristine (1.4 mg/m2 day 1), and oral prednisone (50 mg/day days 1-5).
Before treatment and after 3 and 6 cycles, circulating tumor DNA (ctDNA) was detected to evaluate tumor mutational burden.
The median follow-up was 5 months and all patients completed at least 3 cycles of treatment. The overall response rate was 100.0%: 9 patients achieved a complete response (CR) and 1 patient achieved a partial response. Only 4 patients had received all 6 cycles of treatment, and they all achieved CR and undetectable ctDNA.
The most common hematological adverse events were grade 3-4 decreased lymphocyte counts (70.0%), decreased neutrophil counts (30.0%), thrombocytopenia (20.0%), and anemia (20.0%). Nausea and fatigue were the most common nonhematological adverse events.
The researchers noted that ZR2-CHOP could be a promising treatment choice for high-risk patients with DLBCL.
“ZR2-CHOP for high-risk DLBCL patients with fair physical condition could achieve high CRR and high proportion of early-stage undetectable ctDNA,” they concluded. “The overall tolerability was under control.”
Reference
Zhu H, Sha Y, Wu W, et al. Zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the treatment for diffused large B-cell lymphoma (DLBCL). Presented at: EHA2021 Virtual Congress; June 9-17, 2021. Poster EP548.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen